METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS
A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.
1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . (canceled)
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . A method of treating atherosclerosis or dyslipidemia in a human patient in need of such treatment comprising administering to the patient a combination of nicotinic acid or a pharmaceutically acceptable salt thereof, and a DP receptor antagonist, which selectively modulates the DP receptor and does not substantially modulate a CRTH2 receptor and is
or a pharmaceutically acceptable salt thereof, in amounts that are effective for treating atherosclerosis or dyslipidemia in the absence of substantial flushing.
13 . The method of treatment of claim 12 wherein said combination further comprises an HMG Co-A reductase inhibitor selected from lovastatin, simvastatin, dihydroxy open-acid simvastatin, pravastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin.
14 . The method of treatment of claim 13 wherein said combination further comprises simvastatin.
15 . The method of treatment of claim 13 wherein said combination further comprises atorvastatin.
16 . A method of raising serum HDL levels in a human patient in need of such treatment, comprising administering to the patient a combination of nicotinic acid or a pharmaceutically acceptable salt thereof, and a DP receptor antagonist, which selectively modulates the DP receptor and does not substantially modulate a CRTH2 receptor and is
or a pharmaceutically acceptable salt thereof said combination being effective for raising serum HDL levels in the patient in the absence of substantial flushing.
17 . The method of treatment of claim 16 wherein said combination further comprises an HMG Co-A reductase inhibitor selected from lovastatin, simvastatin, dihydroxy open-acid simvastatin, pravastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin.
18 . The method of treatment of claim 17 wherein said combination further comprises simvastatin.
19 . The method of treatment of claim 17 wherein said combination further comprises atorvastatin.
20 . A method of reducing serum lipoprotein (a) levels, serum VLDL or LDL levels, or serum triglyceride levels in a human patient in need of such treatment, comprising administering to the patient a combination of nicotinic acid or a pharmaceutically acceptable salt thereof, and a DP receptor antagonist, which selectively modulates the DP receptor and does not substantially modulate a CRTH2 receptor and is
or a pharmaceutically acceptable salt thereof said combination being effective for reducing serum lipoprotein(a) levels in the patient in the absence of substantial flushing.
21 . The method of treatment of claim 20 wherein said combination further comprises an HMG Co-A reductase inhibitor selected from lovastatin, simvastatin, dihydroxy open-acid simvastatin, pravastatin, fluvastatin, atorvastatin, pitavastatin and rosuvastatin.
22 . The method of treatment of claim 21 wherein said combination further comprises simvastatin.
23 . The method of treatment of claim 21 wherein said combination further comprises atorvastatin.